Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Mol Cancer Res. 2022 Apr 1;20(4):542–555. doi: 10.1158/1541-7786.MCR-21-0275

Figure 3. Differential phenotypic effects of AXL inhibitors on NSCLC cell lines.

Figure 3.

Relative viability of H1299 (A), H1299 AXL KO (D), PC9 (F), and PC9 AXL KO (I) cells upon 72h treatment with increasing concentrations of the indicated drugs as measured by CellTiterGlo. Data are represented as mean ± SE and is the average of two independent experiments. Colony formation assay of H1299 (B), H1299 AXL KO (E), PC9 (G), and PC9 AXL KO (J) cells post treatment with the indicated doses of RXDX-106, Bemcentinib (Bem), Cabozantinib (Cabo) or Erlotinib (Erlo) for 9 days. Immunoblot analyses showing alterations in downstream signaling in H1299 (C), PC9 (H), and PC9 AXL KO (K) cells when exposed to the indicated concentrations of the different drugs for 1h. Shown is representative of three independent experiments.